Table 3.
Imaging biomarker values of cMRI and phyMRI for the subgroups of patients
| No recurrence | Recurrence | cNB | |||||
|---|---|---|---|---|---|---|---|
| Both TN | FP phyMRI | FP cMRI | Simultan. TP | early TP phyMRI | |||
| early FU (FN cMRI) | subsequ. FU | ||||||
|
ADC [mm2/s] |
1.24 ± 0.31 0.73–1.77 |
1.07 ± 0.40 0.56–1.50 |
2.14 ± 0.65 1.62–2.87 |
1.37 ± 0.34 0.69–1.89 |
1.44 ± 0.33 0.90–1.92 |
1.25 ± 0.25 0.92–1.79 |
0.83 ± 0.10 0.69–1.10 |
|
CBV [%] |
4.7 ± 2.0 2.0–8.9 |
10.6 ± 5.8 6.3–19.0 |
5.0 ± 4.4 2.0–10.0 |
19.9 ± 9.7 7.3–40.0 |
6.5 ± 1.9 3.7–10.6 |
16.8 ± 5.5 7.4–24.7 |
6.2 ± 1.6 3.0–8.8 |
|
µCBV [%] |
2.4 ± 0.7 1.2–3.3 |
5.5 ± 1.8 3.2–7.3 |
1.8 ± 0.6 1.4–2.5 |
7.6 ± 2.2 3.9–13.7 |
3.6 ± 1.3 1.5–5.7 |
7.4 ± 2.0 3.2–10.2 |
3.2 ± 0.8 1.6–4.7 |
|
MVD [mm−2] |
234 ± 41 147–308 |
283 ± 111 122–368 |
107 ± 24 82–130 |
422 ± 160 221–759 |
216 ± 93 80–349 |
379 ± 141 190–577 |
219 ± 57 108–317 |
|
VSI [µm] |
53 ± 11 37–75 |
67 ± 36 23–109 |
66 ± 67 21–143 |
78 ± 27 41–132 |
61 ± 15 31–75 |
65 ± 21 33–100 |
45 ± 15 18–76 |
|
MTI [s−5/2] |
− 0.7 ± 1.1 − 2.9–1.1 |
− 6.9 ± 4.2 − 10.7–1.9 |
− 0.4 ± 0.7 − 1.2–0.1 |
− 29 ± 21 − 72– − 9 |
− 4.6 ± 5.9 − 17.7– − 0.4 |
− 31 ± 11 − 48– − 5.4 |
0.0 ± 1.3 − 2.3–2.7 |
|
OEF [%] |
32 ± 6 24–45 |
44 ± 16 28–64 |
54 ± 26 29–81 |
21 ± 16 5–69 |
38 ± 14 24–69 |
25 ± 12 13–52 |
36 ± 9 22–59 |
|
CMRO2 [µM/100 g∙min] |
80 ± 24 42–120 |
162 ± 62 74–211 |
89 ± 48 56–144 |
120 ± 84 32–342 |
136 ± 55 46–197 |
123 ± 52 53–194 |
101 ± 26 60–153 |
|
PO2 [mmHg] |
41 ± 9 24–57 |
26 ± 10 18–41 |
34 ± 15 20–50 |
55 ± 23 21–88 |
30 ± 15 5–56 |
52 ± 17 24–79 |
35 ± 8 22–54 |
| n | 20 | 3 | 3 | 19 | 15 | 60 | |
Both IDH-mutant astrocytoma WHO grade 3 and oligodendroglioma WHO grade 3 were included in the calculation of the biomarker values. Abbreviations: CBV, cerebral blood volume in macrovasculature; µCBV, CBV in microvasculature; MVD, microvessel density; VSI, vessel size index; MTI, microvessel type indicator; n, patient number in the subgroup; both TN, true negative recurrence detection in cMRI and VAM; FP phyMRI, false positive recurrence detection in physiological MRI; FP cMRI, false positive recurrence detection in cMRI; Simultan. TP, simultaneous and correct glioma WHO grade 3 recurrence detection by both cMRI and phyMRI data; early TP phyMRI, early true positive recurrence detection in phyMRI; early FU, the early follow-up in the “early TP phyMRI” subgroup with a FN finding in the cMRI data; subsequ. FU, the subsequent follow-up in the “early TP phyMRI” subgroup with a delayed TP finding in the cMRI data; cNB, contralateral normal brain